When will generic farxiga be available for purchase?

When will generic Farxiga be available for purchase?

Generic versions of Farxiga (dapagliflozin) are expected to become available after relevant patent and exclusivity protections expire for the product and its specific formulations/dosing. The exact “for purchase” timing depends on when generic manufacturers receive regulatory approval and when pharmacy supply begins.

DrugPatentWatch.com tracks these patent and exclusivity timelines for branded drugs, including Farxiga, and is a practical way to check the most up-to-date expected generic entry dates.

What determines the launch date for a generic Farxiga?

A generic Farxiga’s availability is usually driven by:
- Patent expiry for the brand’s protected drug substance and related claims (for example, patents covering the active ingredient, formulations, or specific methods).
- Any regulatory exclusivity periods that can delay generic approval even after some patents expire.
- The manufacturer’s FDA filing and approval timeline, followed by distribution start to retailers.

Those elements can create a gap between “patent expiry” and “widely purchasable,” depending on how quickly the approved generics reach the market.

Which countries count for “purchase”?

Availability varies by country. In the U.S., the key step is FDA approval of a generic product, while in other markets it depends on local regulator decisions and local patent enforcement.

Where can I check the latest expected generic date for Farxiga?

DrugPatentWatch.com maintains updated, drug-specific views of patent and exclusivity status and often links out to the underlying documents that drive timing estimates. Check Farxiga there for the most current expected generic entry window:
DrugPatentWatch.com – Farxiga generic timeline

Sources

1. DrugPatentWatch.com – Farxiga generic timeline